Scarica l'app Stockscreener
113.75
2.59%
-3.02
Dopo l'orario di chiusura:
114.00
0.25
+0.22%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Biontech Se Adr Borsa (BNTX) Ultime notizie
Will BMY's Oncology Collaborations Drive Its Next Growth Phase? - The Globe and Mail
Should You Buy, Sell or Hold Pfizer Stock Ahead of Q4 Earnings? - Finviz
Goldman Sachs Highlights BioNTech's (BNTX) Immuno-Oncology and ADC Pipeline - Finviz
BioNTech SE (BNTX): A Bull Case Theory - Finviz
BioNTech ernennt Kylie Jimenez zur neuen Personalvorständin - GlobeNewswire Inc.
2 Biotech Stocks Set to Rebound in 2026 - Finviz
Pfizer and BioNTech Move Closer to a Single-Shot Flu–COVID Vaccine: What Investors Should Watch - TipRanks
BioNTech SE Sponsored ADR $BNTX Holdings Boosted by Lbp Am Sa - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Sector Gamma AS Has $2.74 Million Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Baillie Gifford & Co. Lowers Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Bristol-Myers Squibb and BioNTech Advance New Phase 3 Lung Cancer Trial With Pumitamig - TipRanks
Bristol-Myers Squibb and BioNTech Advance New Lung Cancer Weapon Against Keytruda in Phase 3 Trial - TipRanks
BioNTech Shares Gain Momentum on Regulatory and Analyst Support () - aktiencheck.de
BNTX Stock Today: January 23 momentum after six-month high, 2026 catalysts - Meyka
BioNTech (BNTX) soars 11.8%: Is further upside left in the stock? - MSN
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Nasdaq
BioNTech (NASDAQ:BNTX) Trading 7.5% HigherHere's Why - MarketBeat
BioNTech’s BNT142 Trial Termination: What It Means for the Oncology Pipeline and Investors - TipRanks
Five Below Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now? - yourwyominglink.com
What to Expect From Pfizer's Non-Oncology Business in Q4? - The Globe and Mail
BioNTech's Strategic Pivot: A Deep Dive into Its Expanding Oncology Pipeline () - aktiencheck.de
SG Americas Securities LLC Sells 69,726 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It - Chartmill
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan - Yahoo Finance
BioNTech and Bristol-Myers Squibb Push Deeper Into Pancreatic Cancer With New Phase II Trial - TipRanks
BMY Rallies 17.3% in Six Months: Buy, Sell or Hold the Stock? - Finviz
BioNTech Finalizes CureVac Acquisition, Shifts Focus to Integration () - aktiencheck.de
BioNTech: CN Considers to Approve Use of BioNTech Vaccine for Foreigners in CN - AASTOCKS.com
Scientists Question Pfizer, BioNTech's Vaccine Effectiveness - AASTOCKS.com
BioNTech, Pfizer See Covid Vaccine Capacity Rise to 3B Doses Next Yr - AASTOCKS.com
CureVac shares to be delisted from Nasdaq following BioNTech acquisition By Investing.com - Investing.com South Africa
FOSUN PHARMA Pairs with BioNTech to Supply BioNTech Vaccine to Germans in CN - AASTOCKS.com
Pfizer Supplies US Govt with Over 100M Extra Covid Jabs Worth US$3.2B - AASTOCKS.com
CureVac shares to be delisted from Nasdaq following BioNTech acquisition - Investing.com
CureVac’s Final Chapter: BioNTech Completes Acquisition and Delists Shares - AD HOC NEWS
Pfizer Vaccine Effectiveness Sinks to 47% Half Yr Post-inoculation: Research - AASTOCKS.com
BioNTech, Pfizer File Application with EMA for Conditional Marketing Authorization of COVID-19 Vaccine - AASTOCKS.com
BioNTech: Their Vaccine Can Reduce Chance of Catching Severe Covid from Omicron Variant - AASTOCKS.com
Eli Lilly Upgraded, NVIDIA Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - MSN
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Validea's Top Health Care Stocks Based On Benjamin Graham12/29/2025 - Nasdaq
Genmab–BioNTech cancer antibody trial ends early: What investors need to know - MSN
BioNTech SE Sponsored ADR $BNTX Shares Sold by TB Alternative Assets Ltd. - MarketBeat
Genmab–BioNTech Cancer Antibody Trial Ends Early: What Investors Need to Know - TipRanks
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):